PMID- 12646281
OWN - NLM
STAT- MEDLINE
DCOM- 20030703
LR  - 20190726
IS  - 0028-3908 (Print)
IS  - 0028-3908 (Linking)
VI  - 44
IP  - 4
DP  - 2003 Mar
TI  - Reduced social interaction following 3,4-methylenedioxymethamphetamine is not 
      associated with enhanced 5-HT 2C receptor responsivity.
PG  - 439-48
AB  - This study examined the long-term change in serotonergic (5-hydroxytryptamine, 
      5-HT) neuronal function and 5-HT(2C) receptor agonist-induced behaviour following 
      treatment of young rats with 3,4-methylenedioxymethamphetamine (MDMA). On 
      post-natal day (PND) 28, Lister-hooded rats received either MDMA (15 mg/kg i.p.) 
      or saline (1 ml/kg i.p.) twice daily for 3 days. On PND 50 social interaction was 
      assessed between treatment-matched pairs of rats derived from separate litters. 
      The effect of either the 5-HT(2C) receptor agonist, m-chlorophenylpiperazine 
      (m-CPP, 2.5 or 1 mg/kg i.p., respectively) or saline was examined on open-field 
      exploration (PND 52) and elevated plus-maze behaviour (PND 56). Acutely, MDMA 
      produced hyperlocomotion and hypothermia compared with saline injection 
      (p<0.001). Following 20 days abstinence, social interaction was decreased by 26% 
      (p<0.05) in MDMA pre-treated rats compared with saline controls, without any 
      change in locomotion. There was no difference in open-field or elevated plus-maze 
      behaviour between pre-treatment groups. m-CPP caused hypolocomotion in the 
      open-field and decreased both the percentage entries into, and time spent in, the 
      open arms of the elevated plus-maze to a comparable extent in MDMA and saline 
      pre-treated rats. Hippocampal and frontal cortical 5-HT and 5-hydroxyindoleacetic 
      acid (5-HIAA) were significantly reduced in MDMA pre-treated rats, without any 
      change in [(3)H]paroxetine binding or plasma corticosterone levels. These data 
      suggest that the MDMA-induced reduction in social interaction is not mediated via 
      alteration of 5-HT(2C) receptor function.
FAU - Bull, E J
AU  - Bull EJ
AD  - School of Biomedical Sciences, Queen's Medical Centre, University of Nottingham, 
      Nottingham NG7 2UH, UK.
FAU - Hutson, P H
AU  - Hutson PH
FAU - Fone, K C F
AU  - Fone KC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Neuropharmacology
JT  - Neuropharmacology
JID - 0236217
RN  - 0 (Piperazines)
RN  - 0 (Receptor, Serotonin, 5-HT2C)
RN  - 0 (Receptors, Serotonin)
RN  - 0 (Serotonin Agents)
RN  - 0 (Serotonin Receptor Agonists)
RN  - 333DO1RDJY (Serotonin)
RN  - 41VRH5220H (Paroxetine)
RN  - 54-16-0 (Hydroxyindoleacetic Acid)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - REY0CNO998 (1-(3-chlorophenyl)piperazine)
RN  - W980KJ009P (Corticosterone)
SB  - IM
MH  - Animals
MH  - Brain/drug effects/metabolism
MH  - Corticosterone/blood
MH  - Exploratory Behavior/drug effects
MH  - Hydroxyindoleacetic Acid/metabolism
MH  - Hypothermia/chemically induced
MH  - In Vitro Techniques
MH  - Male
MH  - Maze Learning/drug effects
MH  - Motor Activity/drug effects
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*adverse effects
MH  - Paroxetine/metabolism
MH  - Piperazines/pharmacology
MH  - Radioligand Assay
MH  - Rats
MH  - Receptor, Serotonin, 5-HT2C
MH  - Receptors, Serotonin/*drug effects
MH  - Serotonin/metabolism
MH  - Serotonin Agents/*adverse effects
MH  - Serotonin Receptor Agonists/pharmacology
MH  - *Social Behavior
MH  - Substance Withdrawal Syndrome/metabolism/psychology
EDAT- 2003/03/21 04:00
MHDA- 2003/07/04 05:00
CRDT- 2003/03/21 04:00
PHST- 2003/03/21 04:00 [pubmed]
PHST- 2003/07/04 05:00 [medline]
PHST- 2003/03/21 04:00 [entrez]
AID - S0028390802004070 [pii]
AID - 10.1016/s0028-3908(02)00407-0 [doi]
PST - ppublish
SO  - Neuropharmacology. 2003 Mar;44(4):439-48. doi: 10.1016/s0028-3908(02)00407-0.